Peptide Stack for Hormone Optimization: CJC-1295, Ipamorelin, and Kisspeptin

Hormone optimization is one of the most sought-after applications for peptide therapy — and one of the most nuanced. The goal is not to flood the body with exogenous hormones but to support the endogenous signaling cascades that govern growth hormone, testosterone, LH, FSH, and downstream anabolic hormones. Done correctly, peptide-based hormone support preserves natural pulsatility, maintains feedback sensitivity, and avoids the HPTA suppression that comes with exogenous hormone replacement.

This guide covers a clinically informed stack using CJC-1295, ipamorelin, and kisspeptin — three peptides that work at different nodes of the endocrine axis to support optimal hormone production.

The Endocrine Targets

Before building the stack, it helps to map the hormonal pathways involved:

Growth hormone axis: Hypothalamus → GHRH (stimulates) → Pituitary → GH release → Liver → IGF-1 production

Testosterone and LH axis: Hypothalamus → GnRH (pulsatile) → Pituitary → LH + FSH release → Gonads → Testosterone/estrogen production → Kisspeptin neurons (upstream regulation of GnRH)

These two axes interact: GH and IGF-1 support testicular Leydig cell function, and testosterone supports GH receptor expression. A peptide stack that addresses both axes simultaneously creates a reinforcing hormonal environment.

Layer 1: CJC-1295 + Ipamorelin (Growth Hormone Axis)

CJC-1295 (without DAC) is a GHRH analog that extends the duration and amplitude of each pituitary GH pulse. Ipamorelin is a selective GHRP (growth hormone releasing peptide) that mimics ghrelin's action at the pituitary without the cortisol and prolactin elevation seen with older GHRPs. Together, they produce synergistic GH release that can be 2–5 times greater than either compound alone.

From a hormone optimization standpoint, restoring youthful GH pulse amplitude matters because:

• GH declines approximately 15% per decade after age 30
• Low GH is associated with increased visceral fat, reduced lean mass, poor sleep, and fatigue
• GH supports testosterone production through IGF-1 mediated Leydig cell stimulation
• GH improves insulin sensitivity, which supports optimal testosterone metabolism

Protocol:

• CJC-1295 (no DAC): 100–150 mcg
• Ipamorelin: 100–200 mcg
• Administration: Combined subcutaneous injection
• Timing: Before bed (captures the largest natural GH pulse during slow-wave sleep)
• Optional second dose: Fasted morning (empty stomach, minimum 2 hours post-meal for maximum response)
• Cycle: 12–16 weeks on, 4–8 weeks off

For individual compound details, review our CJC-1295 guide and ipamorelin guide.

Layer 2: Kisspeptin (Testosterone Axis)

Kisspeptin is a neuropeptide produced by hypothalamic neurons that is now recognized as one of the primary upstream regulators of the reproductive endocrine axis. It acts on GnRH neurons to stimulate pulsatile GnRH release, which in turn drives LH and FSH secretion from the pituitary, ultimately stimulating testicular testosterone production.

Kisspeptin-10 (the 10-amino-acid fragment) and kisspeptin-54 are the two forms used in research and clinical settings. Kisspeptin-10 is more commonly available as a research peptide.

The evidence base for kisspeptin is particularly strong:

• Published clinical trials at Imperial College London demonstrated that kisspeptin-10 infusion significantly increases LH pulsatility and testosterone in healthy men
• Research shows kisspeptin can partially restore LH pulsatility in men with hypogonadotropic hypogonadism (low testosterone due to hypothalamic/pituitary dysfunction)
• Kisspeptin does not suppress the HPTA — it stimulates it through the natural GnRH pathway

Protocol:

• Dose: 100–300 mcg kisspeptin-10
• Administration: Subcutaneous injection
• Timing: Pulsatile dosing is important — 2–3x per week (not daily, as continuous exposure can desensitize GnRH neurons via receptor downregulation)
• Cycle: 8–12 weeks on, 4 weeks off

This cycling approach mimics the natural episodic nature of kisspeptin signaling and avoids tachyphylaxis.

Blood Work Monitoring Protocol

Hormone optimization without monitoring is guesswork. Establish baseline values before beginning and recheck at 8–12 weeks:

Baseline panel:

• Total testosterone and free testosterone
• LH and FSH
• IGF-1 (proxy for GH axis activity)
• GH (random or stimulation test, though pulsatile release makes random values unreliable)
• Estradiol (E2)
• SHBG (sex hormone-binding globulin)
• Prolactin
• TSH, free T3, free T4 (thyroid — often co-involved in low energy and libido)
• Fasting glucose and HbA1c (IGF-1 and GH affect insulin sensitivity)
• CBC and comprehensive metabolic panel

At 8–12 weeks, recheck:

• Total and free testosterone
• LH and FSH
• IGF-1
• Estradiol and SHBG
• Prolactin (to confirm ipamorelin is not elevating it)

The goal is to see IGF-1 rise toward the upper-normal range (200–350 ng/mL for most adults), LH pulsatility supported or improved, and total testosterone trending upward or at optimal range for age.

Who Benefits Most from This Stack

Men with low-normal testosterone (300–450 ng/dL): This range represents "technically normal" but often symptomatic territory. A GH + kisspeptin stack can push levels toward 600–800 ng/dL without suppressing the HPTA.

Men over 40 experiencing andropause symptoms: Fatigue, reduced libido, difficulty building muscle, increased central fat — these reflect both declining GH and declining testosterone. Addressing both axes simultaneously provides more comprehensive support.

Post-cycle support: Men recovering from anabolic steroid cycles can use kisspeptin during PCT (post-cycle therapy) to support LH recovery while CJC-1295 + ipamorelin address the GH axis independently.

Women with low GH and HPA dysregulation: The GH component of this stack applies across sexes. Women experiencing fatigue, poor body composition, and low IGF-1 can benefit from CJC-1295 + ipamorelin without kisspeptin (which has different implications in the female reproductive axis).

Lifestyle Factors That Amplify Results

Peptide stacks work within the context of your overall physiology. These lifestyle variables can double or halve the effectiveness of hormone optimization:

Sleep: Approximately 70% of daily GH secretion occurs during slow-wave sleep. Seven to nine hours of quality sleep is the single most impactful lifestyle factor for GH axis support. The bedtime CJC-1295 + ipamorelin injection is designed to amplify this natural nocturnal pulse.

Exercise: Resistance training is the strongest natural stimulant of GH and testosterone. High-intensity interval training also stimulates LH pulsatility acutely. Sedentary lifestyle reduces peptide stack effectiveness.

Body fat: Visceral fat (abdominal fat) directly suppresses GH secretion via somatostatin and promotes testosterone aromatization to estrogen. Reducing body fat to below 20% in men substantially improves hormonal response to this stack.

Stress: Chronic cortisol elevation suppresses GnRH pulsatility and GH secretion. Stress management is not optional if hormone optimization is the goal. See our stress and burnout peptide stack for targeted interventions.

Nutrition: Adequate zinc (essential for testosterone biosynthesis), vitamin D (a precursor steroid hormone), and dietary fat (substrate for steroid hormone production) all support the hormonal environment this stack is trying to optimize.

Safety and Contraindications

This stack stimulates, rather than replaces, endogenous hormone production. This means the HPTA remains intact and responsive. Key safety considerations:

• Monitor estradiol: Rising testosterone can aromatize to estrogen; elevated E2 causes gynecomastia, mood changes, and water retention
• Avoid in active cancer or history of hormone-sensitive cancers (prostate, breast)
• Kisspeptin is not appropriate during pregnancy or in women trying to conceive without medical supervision
• Do not stack with testosterone replacement therapy without physician guidance — combined use may over-drive the hormonal axis

Frequently Asked Questions

Q: Will kisspeptin increase testosterone on its own? In men with hypogonadotropic hypogonadism (where the problem is at the hypothalamic/pituitary level), kisspeptin can significantly raise LH and testosterone. In men with primary hypogonadism (testicular failure), it will raise LH but testosterone response will be blunted. Blood work before starting clarifies which scenario applies to you.

Q: How long before testosterone levels respond? LH response to kisspeptin can be seen within hours of a single dose in clinical research. Sustained testosterone elevation typically becomes measurable within 4–6 weeks of consistent pulsatile kisspeptin dosing.

Q: Can I take this stack if I'm already on TRT (testosterone replacement therapy)? The kisspeptin component becomes less relevant if you are exogenously replacing testosterone (your LH is likely already suppressed). CJC-1295 + ipamorelin can still be beneficial for GH axis support independent of testosterone. Discuss with your prescribing physician.

Q: Will this stack affect fertility? Kisspeptin supports the LH/FSH axis that drives spermatogenesis, so it should not negatively impact fertility — and preliminary research suggests it may support it in men with gonadotropin deficiency. Unlike testosterone replacement, it does not suppress sperm production.

Q: What happens when I cycle off? Because this stack stimulates your own hormone production rather than replacing it, cycling off does not create the dramatic crash associated with exogenous testosterone. Your HPTA remains functional. Allow 4–8 weeks off for the CJC-1295/ipamorelin cycle; 4 weeks off for kisspeptin.